


## LX-039

<b>Cat. No.:</b>	HY-143439
<b>CAS No.:</b>	2135341-09-0
<b>Molecular Formula:</b>	C <sub>27</sub> H <sub>20</sub> Cl <sub>2</sub> FNO <sub>2</sub>
<b>Molecular Weight:</b>	480.36
<b>Target:</b>	Estrogen Receptor/ERR
<b>Pathway:</b>	Others
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



## BIOLOGICAL ACTIVITY

<b>Description</b>	LX-039 is a highly potent, selective and orally active estrogen receptor degrader with EC <sub>50</sub> value of 2.29 nM. LX-039 has indole C-3 chlorine atom. LX-039 exhibits excellent mouse pharmacokinetics, low clearance, high C <sub>max</sub> and oral exposure. LX-039 has anti-tumor activity <sup>[1]</sup> .																									
<b>IC<sub>50</sub> &amp; Target</b>	Estrogen receptor 2.29 nM (EC <sub>50</sub> )																									
<b>In Vivo</b>	<p>LX-039 (2.5 mg/kg; PO and IV; single) exhibits excellent mouse pharmacokinetics, low clearance, high C<sub>max</sub> and oral exposure<sup>[1]</sup>.</p> <p>LX-039 (6.5 mg/kg, 20 mg/kg and 60 mg/kg; PO; daily for 21 days) inhibits tumor growth in a dose-dependent manner<sup>[1]</sup>.</p> <p>LX-039 (1 mg/kg; PO and IV; single) displays a moderate to low clearance (Cl) plus good oral bioavailability (F%) in both rat and dog<sup>[1]</sup>.</p> <p>Pharmacokinetic Parameters of LX-039 in CD-1 mouse<sup>[1]</sup>.</p> <table border="1"> <thead> <tr> <th></th> <th>IV</th> <th>PO (2.5 mg/kg)</th> </tr> </thead> <tbody> <tr> <td>Vd (L/kg)</td> <td>0.5</td> <td></td> </tr> <tr> <td>CL (mL/min/kg)</td> <td>1.4</td> <td></td> </tr> <tr> <td>C<sub>max</sub> (nM)</td> <td></td> <td>1873</td> </tr> <tr> <td>AUC<sub>0-24</sub> (nM·h)</td> <td></td> <td>15329</td> </tr> <tr> <td>F (%)</td> <td></td> <td>60.1</td> </tr> </tbody> </table> <p>Pharmacokinetic Parameters of LX-039 in SD rat and Beagle dog<sup>[1]</sup>.</p> <table border="1"> <thead> <tr> <th></th> <th>SD Rat</th> <th>Beagle Dog</th> </tr> </thead> <tbody> <tr> <td></td> <td></td> <td></td> </tr> </tbody> </table>			IV	PO (2.5 mg/kg)	Vd (L/kg)	0.5		CL (mL/min/kg)	1.4		C <sub>max</sub> (nM)		1873	AUC <sub>0-24</sub> (nM·h)		15329	F (%)		60.1		SD Rat	Beagle Dog			
	IV	PO (2.5 mg/kg)																								
Vd (L/kg)	0.5																									
CL (mL/min/kg)	1.4																									
C <sub>max</sub> (nM)		1873																								
AUC <sub>0-24</sub> (nM·h)		15329																								
F (%)		60.1																								
	SD Rat	Beagle Dog																								

---

Vd (L/kg, iv)	2	0.42
CL (mL/min/kg, iv)	7.7	0.84
C <sub>0</sub> , iv (nM), 1 mg/kg	2610	12800
AUC <sub>0-24</sub> , iv (nM·h), 1 mg/kg	4820	43800
C <sub>max</sub> , po (nM), 1 mg/kg	381	2550
AUC <sub>0-24</sub> , po (nM·h), 1 mg/kg	2700	24200
F (%)	56	55

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## REFERENCES

---

[1]. Lu J, Chan CC, Sun D, et al. Discovery and preclinical profile of LX-039, a novel indole-based oral selective estrogen receptor degrader (SERD). *Bioorg Med Chem Lett.* 2022;66:128734.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA